Corporate
-
Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease QuickFire Challenge
Largest QuickFire competition to date will award up to $500,000 in a research grant and entrance to Johnson & Johnson Innovation, JLABS, to promising transformational healthcare solution Challenge launched at 2016 BIO International Convention during the Bionic Innovation Forum -
Yoshinori Ohsumi, Ph.D., Wins 2016 Dr. Paul Janssen Award for Biomedical Research
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy. -
Boomer Esiason Foundation Announces Collaboration with Johnson & Johnson for First-of-Its-Kind TRU Heroes Cystic Fibrosis Nursing Program
$1,000,000 program funded by Johnson & Johnson will be the first to help nurses specialize in cystic fibrosis education -
Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa
DREAMS Partners Announce $85 Million Innovation Challenge Focused on Solutions for Adolescent Girls and Young Women -
Johnson & Johnson Health and Wellness Solutions Teams with Plug and Play to Launch Health and Wellness Technology Accelerator
Announces Call for Wellness Startups for 2016 Accelerator -
-
-
-
Important Global Data from XARELTO® EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015
The EXPLORER program is unmatched by any non-vitamin K oral anticoagulant (NOAC) in its size, scope and ambition and continues to generate important clinical evidence on XARELTO® (rivaroxaban)